June 24, 2024 | Monday | News
The pharmaceutical industry has witnessed a transformative journey from 2000 to 2024, marked by numerous significant mergers and acquisitions (M&A).
The following report provides detailed analysis of Mergers and Acquisitions of BioPharma and Pharmaceuticals companies until 2024, from 2000. It provides details about the acquirer, acquired company, the transaction process, stating if it was a fully cash deal or both cash and equity deal. The report tries to provides details about equity dealings by providing insights about per share values, stake in the acquired company and its EPS growth respectively.
The highest amount of transaction carried out up till 2024 was by Glaxo Wellcome and SmithKline Beecham in the 2000. The merger resulted into the formation of GlaxoSmithKline a world leading brand in the pharmaceutical industry with a transaction value of $76 billion, with adjusting inflation this transaction can be valued up to $134.5 billion.
Summary: In 2024, several significant acquisitions took place in the pharmaceutical and biotechnology sectors:
AstraZeneca:
Bristol Myers Squibb:
Novartis:
Telix Pharmaceuticals:
Sanofi:
Gilead Sciences:
Novo Holdings:
Genmab:
Endo International:
Ono Pharmaceuticals:
Johnson & Johnson:
Novo Nordisk:
Summary: In 2023, Bristol Myers Squibb (BMS) made several significant acquisitions in the pharmaceutical sector:
Bristol Myers Squibb (BMS):
Auro Pharma:
Nirma:
Pfizer:
Summary: In 2022, several significant acquisitions took place in the pharmaceutical and biotech industries:
Amgen:
Pfizer:
Bristol Myers Squibb:
Amgen:
Biocon:
GlaxoSmithKline:
Sumitomo:
Summary: In 2021, several notable acquisitions occurred in the biopharmaceutical industry:
CSL Ltd.:
Merck:
Jazz Pharmaceuticals:
Pfizer:
Novo Nordisk:
Sanofi:
Horizon Therapeutics:
Pfizer:
Perrigo:
Amgen:
Sanofi:
Summary: In 2020, the pharmaceutical industry saw several significant mergers and acquisitions:
AstraZeneca:
Gilead Sciences:
Bristol Myers Squibb:
Johnson & Johnson:
Gilead Sciences:
Sanofi:
Merck:
Bayer:
Summary: In 2019, several significant mergers and acquisitions took place in the pharmaceutical and biotechnology sectors:
Grifols SA:
Thermo Fisher Scientific Inc.:
FUJIFILM Corporation:
Ligand Pharmaceuticals Incorporated:
Biogen:
Pfizer:
Merck:
Bristol Myers Squibb:
AbbVie Inc.:
GlaxoSmithKline and Pfizer:
Pfizer and Mylan:
Summary: In 2018, several notable acquisitions took place in the pharmaceutical and biotechnology industries:
GlaxoSmithKline:
Novartis:
AstraZeneca:
Taisho Pharmaceuticals:
Bayer:
Takeda Pharmaceuticals Limited:
Summary: In 2017, Dr. Reddy's Laboratories Ltd. and Taro Pharma made notable acquisitions:
Dr. Reddy's Laboratories Ltd.:
Taro Pharma:
In 2016, Bayer and Abbott Laboratories made significant moves:
Bayer:
Shire Plc:
Abbott Laboratories:
Summary: In 2015, Actavis, Teva, and Pfizer were key players in significant acquisitions:
Actavis:
Teva Pharmaceutical Industries:
AbbVie:
Pfizer:
In 2014, Actavis Generics made a major move:
In 2013, Amgen and GlaxoSmithKline expanded their portfolios:
Amgen:
Gilead Sciences:
Summary: In 2011, 2010, and 2009, several major acquisitions occurred:
Gilead Sciences:
Abbott:
Merck:
Roche:
Pfizer:
Summary: From 2000 to 2008, several transformative mergers took place:
Glaxo Wellcome:
Sanofi:
Pfizer:
Bayer:
CVS Health:
These summaries provide a clear and organized view of the most significant M&A deals in the pharmaceutical industry from 2000 to 2024, highlighting the key players and the strategic impacts of these transactions
The series of mergers and acquisitions from 2000 to 2024 highlight significant strategic moves within the pharmaceutical industry aimed at expanding market share, enhancing research and development capabilities, and achieving synergies. The 2000 merger of Glaxo Wellcome and SmithKline Beecham to form GlaxoSmithKline (GSK) set a precedent for large-scale consolidations, valued at $76 billion ($134.5 billion inflation-adjusted). Sanofi's 2004 acquisition of Aventis for $64.2 billion ($103.6 billion adjusted) further exemplified the industry's drive towards creating global pharmaceutical powerhouses. Pfizer's 2002 acquisition of Pharmacia Corp for $60 billion strengthened its market leadership.
In 2006, Bayer's $21.5 billion takeover of Schering AG and CVS Health's $21 billion merger with Caremark RX reflected continued consolidation efforts to enhance product portfolios and market presence. Moving forward to 2015, notable transactions included Actavis's $70.5 billion acquisition of Allergan Inc., Teva's $40.5 billion purchase of Allergan Plc’s generic drug business, AbbVie's $21 billion acquisition of Pharmacyclics, and Pfizer’s $17 billion purchase of Hospira, indicating a trend towards securing specialty drugs and biotechnology capabilities.
The acquisitions from 2016 and 2017, including Bayer’s $62 billion purchase of Monsanto and CVS Health’s $69 billion acquisition of Aetna, illustrate the industry's evolving focus towards integrating healthcare services and expanding into related sectors. These deals reflect a strategic shift aimed at addressing broader healthcare needs and achieving long-term growth in a competitive landscape. Collectively, these mergers and acquisitions underscore the pharmaceutical industry's relentless pursuit of growth, innovation, and market dominance through strategic consolidation.
© Copyright 2024, MM Activ Sci-Tech Communications. All Rights Reserved.
Website Design & Developed By : SCI Knowledge Interlinks